Published in MAbs on April 11, 2013
Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One (2013) 0.94
Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG. J Virol (2013) 0.85
The making of bispecific antibodies. MAbs (2017) 0.84
Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother (2016) 0.80
Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis (2015) 0.79
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep (2014) 0.78
An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo. MAbs (2014) 0.77
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs (2016) 0.77
Development of a high affinity, non-covalent biologic to add functionality to Fabs. Sci Rep (2015) 0.76
Tetraspecific ligand for tumor-targeted delivery of nanomaterials. Biomaterials (2014) 0.75
Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation. Bioconjug Chem (2016) 0.75
Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. MAbs (2016) 0.75
Affibody molecules as engineered protein drugs. Exp Mol Med (2017) 0.75
TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations. Protein Eng Des Sel (2016) 0.75
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
ProPred: prediction of HLA-DR binding sites. Bioinformatics (2001) 4.39
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol (1998) 2.65
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer (2010) 2.51
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) 2.50
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng (1996) 2.44
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
Domain antibodies: proteins for therapy. Trends Biotechnol (2003) 2.15
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther (2010) 1.99
Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res (2009) 1.86
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.70
Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem (2010) 1.60
Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res (2010) 1.59
Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res (2008) 1.55
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther (2012) 1.53
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol (1995) 1.53
Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res (2009) 1.38
Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol (2007) 1.33
Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel (2010) 1.27
A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng (1995) 1.23
Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs (2010) 1.17
An efficient chemical approach to bispecific antibodies and antibodies of high valency. Bioorg Med Chem Lett (2009) 1.11
Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res (2008) 1.07
Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. J Mol Biol (2012) 1.00
New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R D (2008) 0.99
Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng Des Sel (2010) 0.91
Peptibodies: A flexible alternative format to antibodies. MAbs (2012) 0.91
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs (2012) 0.89
Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem (2010) 0.86
Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int J Oncol (2010) 0.85
Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Cancer (2004) 0.84
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
De novo computational design of retro-aldol enzymes. Science (2008) 7.62
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37
Engineering polydactyl zinc-finger transcription factors. Nat Biotechnol (2002) 4.40
Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res (2006) 3.95
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity (2002) 3.46
Custom zinc-finger nucleases for use in human cells. Mol Ther (2005) 3.04
Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol (2003) 2.75
Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors. J Biol Chem (2005) 2.69
Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol (2010) 2.65
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum (2003) 2.47
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum (2003) 2.47
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Designing transcription factor architectures for drug discovery. Mol Pharmacol (2004) 2.44
IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med (2010) 2.36
Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry (2003) 2.33
Characterization of cardiac tumors in children by cardiovascular magnetic resonance imaging: a multicenter experience. J Am Coll Cardiol (2011) 2.24
Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum (2003) 2.21
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum (2006) 2.17
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol (2002) 2.16
Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum (2009) 2.14
Type I interferon: potential therapeutic target for psoriasis? PLoS One (2008) 2.08
Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat Methods (2012) 2.07
Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol (2002) 2.00
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97
Synthesis of programmable integrases. Proc Natl Acad Sci U S A (2009) 1.94
Enamine-based organocatalysis with proline and diamines: the development of direct catalytic asymmetric Aldol, Mannich, Michael, and Diels-alder reactions. Acc Chem Res (2004) 1.92
Structure of Aart, a designed six-finger zinc finger peptide, bound to DNA. J Mol Biol (2006) 1.91
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis (2011) 1.91
Modular system for the construction of zinc-finger libraries and proteins. Nat Protoc (2010) 1.87
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol (2010) 1.86
Rapid, stable, chemoselective labeling of thiols with Julia-Kocieński-like reagents: a serum-stable alternative to maleimide-based protein conjugation. Angew Chem Int Ed Engl (2013) 1.85
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 1.80
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci U S A (2003) 1.78
YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol (2008) 1.78
BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol (2002) 1.77
Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J (2004) 1.77
Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum (2007) 1.72
Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood (2007) 1.64
TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model. Nat Biotechnol (2003) 1.63
Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry (2002) 1.60
Functional replacement and positional dependence of homologous and heterologous L domains in equine infectious anemia virus replication. J Virol (2002) 1.60
Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J Immunol (2003) 1.57
An infectious West Nile virus that expresses a GFP reporter gene. Virology (2005) 1.51
The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol (2012) 1.49
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol (2010) 1.41
Chimeric TALE recombinases with programmable DNA sequence specificity. Nucleic Acids Res (2012) 1.38
Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. Int J Cancer (2006) 1.37
Anomalous right coronary artery from the pulmonary artery: noninvasive diagnosis and serial evaluation. J Cardiovasc Magn Reson (2007) 1.36
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther (2006) 1.36
Incomplete double aortic arch with atresia of the distal left arch: distinctive imaging appearance. AJR Am J Roentgenol (2005) 1.35
Heritable endogenous gene regulation in plants with designed polydactyl zinc finger transcription factors. Proc Natl Acad Sci U S A (2002) 1.34
In vivo site-specific DNA methylation with a designed sequence-enabled DNA methylase. J Am Chem Soc (2007) 1.33
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother (2005) 1.32
Structure-guided reprogramming of serine recombinase DNA sequence specificity. Proc Natl Acad Sci U S A (2010) 1.31
Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection. J Mol Biol (2004) 1.30
Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol (2003) 1.30
Exploring strategies for the design of artificial transcription factors: targeting sites proximal to known regulatory regions for the induction of gamma-globin expression and the treatment of sickle cell disease. J Biol Chem (2004) 1.30
Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. J Med Chem (2004) 1.29
Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. AJR Am J Roentgenol (2008) 1.29
Evolution of programmable zinc finger-recombinases with activity in human cells. J Mol Biol (2007) 1.28
Breaking the one antibody-one target axiom. Proc Natl Acad Sci U S A (2006) 1.26
Direct asymmetric alpha-fluorination of aldehydes. Angew Chem Int Ed Engl (2005) 1.25
A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res (2008) 1.25
BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem (2004) 1.25
Instant immunity through chemically programmable vaccination and covalent self-assembly. Proc Natl Acad Sci U S A (2009) 1.25
Attenuation of HIV-1 replication in primary human cells with a designed zinc finger transcription factor. J Biol Chem (2004) 1.24
Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci (2009) 1.23
Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum Genomics Proteomics (2009) 1.22
Unconventional secretion of tissue transglutaminase involves phospholipid-dependent delivery into recycling endosomes. PLoS One (2011) 1.22
Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg Med Chem Lett (2006) 1.22
Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes. PLoS One (2011) 1.20
Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J Virol (2004) 1.20
Directed evolution of recombinase specificity by split gene reassembly. Nucleic Acids Res (2010) 1.19
Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses (2008) 1.19
Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol (2011) 1.18
Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. Cancer Res (2007) 1.15
Core-structure-motivated design of a phosphine-catalyzed [3+2] cycloaddition reaction: enantioselective syntheses of spirocyclopenteneoxindoles. J Am Chem Soc (2011) 1.15
Development of a long-acting insulin analog using albumin fusion technology. Diabetes (2005) 1.14
Towards organo-click chemistry: development of organocatalytic multicomponent reactions through combinations of aldol, Wittig, Knoevenagel, Michael, Diels-Alder and Huisgen cycloaddition reactions. Chemistry (2004) 1.14
The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol (2009) 1.14
Application of 3-D printing (rapid prototyping) for creating physical models of pediatric orthopedic disorders. Pediatr Radiol (2013) 1.13
Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase. Nucleic Acids Res (2011) 1.13
Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis (2008) 1.13
Organocatalytic asymmetric domino knoevenagel/diels-alder reactions: a bioorganic approach to the diastereospecific and enantioselective construction of highly substituted spiro[5,5]undecane-1,5,9-triones. Angew Chem Int Ed Engl (2003) 1.12
Optimal imaging strategy for community-acquired Staphylococcus aureus musculoskeletal infections in children. Pediatr Radiol (2008) 1.12
Development of small designer aldolase enzymes: catalytic activity, folding, and substrate specificity. Biochemistry (2005) 1.12
Differential EphA2 epitope display on normal versus malignant cells. Cancer Res (2003) 1.12
A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J Mol Biol (2003) 1.11
Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J (2002) 1.11